Seropositivity of HPV 16 E6 and E7 and the risk of oral cancer

被引:5
|
作者
Wong, G. R. [1 ,2 ]
Ha, K. O. [2 ]
Himratul-Aznita, W. H. [3 ]
Yang, Y. H. [4 ]
Mustafa, W. M. Wan [5 ]
Yuen, K. M. [5 ]
Abraham, M. T. [5 ]
Tay, K. K. [5 ]
Karen-Ng, L. P. [1 ]
Cheong, S. C. [2 ,6 ]
Zain, R. B. [1 ,2 ]
机构
[1] Univ Malaya, OCRCC, Fac Dent, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Fac Dent, Dept Oro Maxillofacial Surg & Med Sci, Kuala Lumpur 50603, Malaysia
[3] Univ Malaya, Fac Dent, Dept Oral Biol & Biomed Sci, Kuala Lumpur 50603, Malaysia
[4] Kaohsiung Med Univ Hosp, Sch Pharm, Kaohsiung, Taiwan
[5] Minist Hlth Malaysia, Oral Hlth Div, Putrajaya, Malaysia
[6] Sime Darby Med Ctr, Oral Canc Res Team, Canc Res Initiat Fdn CARIF, Subang, Jaya, Malaysia
关键词
oral cancer; human papillomavirus 16; E6 and E7 oncoproteins; ELISA; SQUAMOUS-CELL CARCINOMA; PAPILLOMAVIRUS TYPE-16 INFECTION; NECK; HEAD; VIRUS; PREVALENCE;
D O I
10.1111/odi.12218
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
ObjectivesThe objective of the study was to determine the prevalence of HPV seropositivity among patients with oral squamous cell carcinoma (OSCC) and healthy individuals and to correlate the association between HPV 16 seropositivity and risk of OSCC. Materials and MethodsHPV 16 E6 and E7 plasmids were constructed for the production of recombinant protein, which was used as the antigen in ELISA. HPV ELISA was performed on serum samples from 50 healthy individuals and 50 patients with OSCC. ResultsUsing the HPV ELISA, 30% (OR=2.25, 95% CI=0.85-5.93) and 18% (OR=1.61, 95% CI=0.53-4.92) of patients with oral cancer were found to be HPV 16 E6 and E7 seropositive, respectively. Significant association was found between HPV 16 seropositivity and increased risk of OSCC in men, but not in male subjects. A similar trend was observed in non-betel quid chewers. ConclusionsPotential associations between HPV 16 E6/E7 seropositivity and oral cancer were revealed in men and non-betel quid chewer subjects, suggesting a possible etiological role of HPV 16 in subgroup of patients with OSCC in Malaysia.
引用
收藏
页码:762 / 767
页数:6
相关论文
共 50 条
  • [31] A Comparative Evaluation of HPV OncoTect E6 E7 mRNA and Cervista HPV 16/18 Tests on High-Risk HPV Samples
    Noy, M. A.
    Paz, J. R.
    Rosado, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 872 - 873
  • [32] A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors
    B G Wieking
    D W Vermeer
    W C Spanos
    K M Lee
    P Vermeer
    W T Lee
    Y Xu
    E S Gabitzsch
    S Balcaitis
    J P Balint
    F R Jones
    J H Lee
    Cancer Gene Therapy, 2012, 19 : 667 - 674
  • [33] Analysis of oncogenes E6 and E7 variants in 78 women infected with HPV-16
    Coste-Burel, M
    Besse, B
    Papy, K
    Lopes, P
    Laboisse, C
    Imbertmarcille, BM
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S101 - S101
  • [34] 云南HPV-16型E6、E7基因的突变分析
    张晓琳
    刘峰
    姚月婷
    李亚东
    周竞贤
    易力
    姚宇峰
    俞建昆
    微生物学杂志, 2014, 34 (02) : 17 - 23
  • [35] CONSERVATION OF HPV-16 E6/E7 ORF SEQUENCES IN A CERVICAL-CARCINOMA
    CONE, RW
    MINSON, AC
    SMITH, MR
    MCDOUGALL, JK
    JOURNAL OF MEDICAL VIROLOGY, 1992, 37 (02) : 99 - 107
  • [36] Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes
    Alvarez-Salas, LM
    Cullinan, AE
    Siwkowski, A
    Hampel, A
    DiPaolo, JA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) : 1189 - 1194
  • [37] Molecular and evolutionary analysis of HPV16 E6 and E7 genes in Greek women
    Tsakogiannis, D.
    Papadopoulou, A.
    Kontostathi, G.
    Ruether, I. G. A.
    Kyriakopoulou, Z.
    Dimitriou, T. G.
    Orfanoudakis, G.
    Markoulatos, P.
    JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 62 : 1688 - 1696
  • [38] Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer
    Smith, Elaine M.
    Pawlita, Michael
    Rubenstein, Linda M.
    Haugen, Thomas H.
    Hamsikova, Eva
    Turek, Lubomir P.
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (01) : 111 - 117
  • [39] In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma
    Madrigal, M
    Janicek, MF
    Sevin, BU
    Perras, J
    Estape, R
    Penalver, M
    Averette, HE
    GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 18 - 25
  • [40] HPV16 immunity induced by immune responses to mutations in E6 and E7 proteins
    Agarwal, Maria
    Saint-Fleur, Ashley
    Fu, Jie
    Levitsky, Hyam
    Trimble, Cornelia L.
    CANCER RESEARCH, 2015, 75